Key facts
- It has raised $32.0M; the latest was Early Stage VC ($32.0M) in Nov 2025.
- Notable investors include MVM Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Avanzanite Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Avanzanite Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avanzanite Bioscience
Operator of a biopharmaceutical company intended to redefine the commercialization of orphan medicines to improve patient access to medicines for rare diseases. The company offers end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their novel medicines for patients who suffer from orphan diseases, enabling medical professionals to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical partners.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2021
- Employees
- 14
- Website
- avanzanite.com/
- Ownership
- Privately Held (backing)
Avanzanite Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avanzanite Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avanzanite Bioscience in its N-PORT filings yet. We sweep new filings monthly.